Cargando…

Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications

INTRODUCTION: Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido-Mesa, Jose, Adams, Kate, Galvez, Julio, Garrido-Mesa, Natividad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115781/
https://www.ncbi.nlm.nih.gov/pubmed/35294307
http://dx.doi.org/10.1080/13543784.2022.2054325
_version_ 1784709990716538880
author Garrido-Mesa, Jose
Adams, Kate
Galvez, Julio
Garrido-Mesa, Natividad
author_facet Garrido-Mesa, Jose
Adams, Kate
Galvez, Julio
Garrido-Mesa, Natividad
author_sort Garrido-Mesa, Jose
collection PubMed
description INTRODUCTION: Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and experimental reports suggest a direct antiviral activity against SARS-CoV2. Furthermore, a few clinical reports indicate their potential in COVID-19 patients. In addition to the scarcity and limitations of the scientific evidence, the effectiveness of tetracyclines in experimental ARDS has been proven extensively, counteracting the overt inflammatory reaction and fibrosis sequelae due to a synergic combination of pharmacological activities. AREAS COVERED: This paper discusses the scientific evidence behind the application of tetracyclines for ARDS/COVID-19. EXPERT OPINION: The benefits of their multi-target pharmacology and their safety profile overcome the limitations, such as antibiotic activity and low commercial interest. Immunomodulatory tetracyclines and novel chemically modified non-antibiotic tetracyclines have therapeutic potential. Further drug repurposing studies in ARDS and severe COVID-19 are necessary.
format Online
Article
Text
id pubmed-9115781
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91157812022-05-18 Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications Garrido-Mesa, Jose Adams, Kate Galvez, Julio Garrido-Mesa, Natividad Expert Opin Investig Drugs Review INTRODUCTION: Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and experimental reports suggest a direct antiviral activity against SARS-CoV2. Furthermore, a few clinical reports indicate their potential in COVID-19 patients. In addition to the scarcity and limitations of the scientific evidence, the effectiveness of tetracyclines in experimental ARDS has been proven extensively, counteracting the overt inflammatory reaction and fibrosis sequelae due to a synergic combination of pharmacological activities. AREAS COVERED: This paper discusses the scientific evidence behind the application of tetracyclines for ARDS/COVID-19. EXPERT OPINION: The benefits of their multi-target pharmacology and their safety profile overcome the limitations, such as antibiotic activity and low commercial interest. Immunomodulatory tetracyclines and novel chemically modified non-antibiotic tetracyclines have therapeutic potential. Further drug repurposing studies in ARDS and severe COVID-19 are necessary. Taylor & Francis 2022-03-23 /pmc/articles/PMC9115781/ /pubmed/35294307 http://dx.doi.org/10.1080/13543784.2022.2054325 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
spellingShingle Review
Garrido-Mesa, Jose
Adams, Kate
Galvez, Julio
Garrido-Mesa, Natividad
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
title Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
title_full Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
title_fullStr Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
title_full_unstemmed Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
title_short Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications
title_sort repurposing tetracyclines for acute respiratory distress syndrome (ards) and severe covid-19: a critical discussion of recent publications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115781/
https://www.ncbi.nlm.nih.gov/pubmed/35294307
http://dx.doi.org/10.1080/13543784.2022.2054325
work_keys_str_mv AT garridomesajose repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications
AT adamskate repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications
AT galvezjulio repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications
AT garridomesanatividad repurposingtetracyclinesforacuterespiratorydistresssyndromeardsandseverecovid19acriticaldiscussionofrecentpublications